53 results about "Ginsenoside Rg1" patented technology

The invention discloses design and synthesis of a series of brain-targeted ginsenoside Rg1 derivatives and application of the brain-targeted ginsenoside Rg1 derivatives in treatment of Alzheimer's disease. According to the invention, ginsenoside Rg1 and polyethylene glycol with a specific chain length are covalently linked to successfully construct the derivative capable of enhancing the penetrating power of the blood-brain barrier. The series of derivatives provided by the invention not only solve the problems of poor brain targeting and insufficient stability of natural Rg1, but also can inhibit neuroinflammation by regulating and controlling an NLRP3 / caspase-1 signal channel in an LPS-induced neuroinflammation model, and finally, the learning and memory ability is remarkably improved. The product is simple and convenient in preparation process and good in biological safety, and a new candidate compound is provided for developing a new generation of Alzheimer disease treatment medicines.

The application discloses a SNP site and KASP marker combination related to contents and proportions of ginsenosides Rg1 and Rb1 in Panax notoginseng and application thereof, and belongs to the technical field of medicinal plant molecular breeding and quality evaluation. In view of the problems of lack of molecular markers synchronously related to contents and proportions of ginsenosides Rg1 and Rb1 in Panax notoginseng and long breeding cycle in the prior art, nine SNP site combinations located on a Chr11 chromosome of Panax notoginseng genome are screened, and a KASP marker combination and primer combination are developed based on four sites of SNP3-SNP6 among them. The KASP marker combination has strong specificity, is convenient to detect, has high throughput, is low in cost, and can accurately identify the contents and proportions of Rg1 and Rb1 in Panax notoginseng samples. The application can be used for Panax notoginseng germplasm resource screening and molecular marker assisted breeding, early identification of target traits is realized, the breeding cycle is shortened, the breeding efficiency is improved, and technical support is provided for directional cultivation of Panax notoginseng high-quality varieties.

The application discloses an application of a kit for detecting a SNP molecular marker related to the content of ginsenoside Rg1 in panax notoginseng in breeding of the content of ginsenoside Rg1 in panax notoginseng, wherein the SNP molecular marker is SNP4-117624472, is located at the 117624472th base of a Chr11 chromosome, and the mutation type is C / A. The KASP primer combination developed in the application can accurately distinguish panax notoginseng with high and low contents of ginsenoside Rg1, and can be applied to molecular assisted marker breeding of panax notoginseng, shortens the breeding cycle of new varieties, and has low detection cost, is not limited by environment, has high accuracy of detection results, and is easy to repeat. The application has important theoretical and practical guiding significance for accelerating the genetic improvement process of panax notoginseng with high content of ginsenoside Rg1 and improving the breeding selection efficiency.

The invention relates to the technical field of medicines for treating intestinal ischemia-reperfusion injury, and discloses a medicine for treating intestinal ischemia-reperfusion injury and a preparation method thereof. Comprising 10 to 25 parts of rosmarinic acid, 5 to 15 parts of betaine, 3 to 10 parts of glutamine, 10 to 25 parts of salvianolic acid B, 5 to 15 parts of astragaloside, 3 to 10 parts of ginsenoside Rg1, 2 to 8 parts of curcumin, 5 to 12 parts of ophiopogon japonicus polysaccharide, 2 to 6 parts of notoginsenoside R1, 3 to 7 parts of total flavonoids of oldenlandia diffusa and 4 to 9 parts of angelica sinensis polysaccharide. The medicine disclosed by the invention can be used for relieving intestinal edema, repairing oxidative injury, clearing excessive ROS, improving SOD activity, blocking oxidative stress injury, inhibiting epithelial cell apoptosis, reducing intestinal permeability and maintaining mucous membrane integrity, and has an excellent treatment effect on intestinal ischemia reperfusion injury.

This invention discloses a kit for detecting SNP molecular markers related to the content of ginsenoside Rg1 in Panax notoginseng, and its application in breeding for the ginsenoside Rg1 content trait in Panax notoginseng. The SNP molecular marker is SNP8-117644135, located at base 117644135 on chromosome Chr11, with a mutation type of C / T. The KASP primer combination developed in this invention can accurately distinguish between Panax notoginseng with high and low ginsenoside Rg1 content, and can be applied to molecular marker-assisted breeding of Panax notoginseng, shortening the breeding cycle of new varieties. Furthermore, the detection cost is low, it is not limited by the environment, and the detection results are highly accurate and easily reproducible. This has important theoretical and practical guiding significance for accelerating the genetic improvement process of breeding Panax notoginseng with high ginsenoside Rg1 content and improving breeding selection efficiency.

The invention discloses a micropterus salmoides rhabdovirus attenuated freeze-dried vaccine activator. The micropterus salmoides rhabdovirus attenuated freeze-dried vaccine activator comprises ginsenoside Rg1. The invention further discloses application of the ginsenoside Rg1 in preparation of the micropterus salmoides rhabdovirus attenuated freeze-dried vaccine and a method for activating the micropterus salmoides rhabdovirus attenuated freeze-dried vaccine. After the ginsenoside Rg1 is used for activating the vaccine, the virus titer is high, the high activity of the freeze-dried vaccine can be maintained, the immune protection effect of the largemouth bass rhabdovirus attenuated freeze-dried vaccine can be remarkably improved through soaking immunization, and a foundation is laid for application of the largemouth bass rhabdovirus attenuated vaccine.

Provided is a pharmaceutical composition and application thereof, specifically, said pharmaceutical composition comprises: salvianolic acid B as a first active ingredient; and ginsenoside Rg1 as a second active ingredient, and the weight ratio of the first active ingredient to the second active ingredient being 5:(1-4.5). The pharmaceutical composition has a better active-ingredient proportion than the prior art, has a better therapeutic efficacy in preventing and / or treating ischemic diseases, and ischemia-reperfusion tissue or organ damage, and can be used for treating ischemia and / or ischemia-reperfusion damage of different tissues and organs.

The application discloses a kind of β-glucosidase GE000505 for saponin conversion and its preparation method and application, belong to biotechnology field, the amino acid sequence of the β-glucosidase GE000505 as shown in SEQ ID NO.1, it is encoded by the gene with nucleotide sequence as shown in SEQ ID NO.2.This β-glucosidase GE000505 of the application can convert high content ginseng and sanchi saponin into rare saponin R2, Rg3, Rg2 and Rh1, can convert sanchi saponin R1 into R2 entirely, convert ginsenoside Rd into Rg3 entirely, convert ginsenoside Re into Rg2 entirely, convert ginsenoside Rg1 into Rh1 entirely, convert ginsenoside F1 into aPPT entirely, convert ginsenoside F2 into aPPD entirely, solve the problem that existing β-glucosidase is not resistant to alcohol in the conversion of ginsenoside.

The application provides a composition for improving intestinal digestive enzyme activity and application thereof, and belongs to the technical field of animal medicine. The composition is composed of double-kidney polysaccharide, ginsenoside Rb1 and ginsenoside Rg1. In the composition, the mass ratio of the double-kidney polysaccharide, the ginsenoside Rb1 and the ginsenoside Rg1 is 90:5:5 or 95:2.5:2.5, preferably 90:5:5, and the intestinal digestive enzyme is specifically duodenal trypsin and amylase. Experimental results show that the composition can significantly synergistically improve the activities of the duodenal trypsin and amylase of laying hens, improve the feed utilization rate, thereby improve the egg production rate, improve the egg weight and the eggshell strength, and effectively improve the breeding benefit of the laying hens.

The invention belongs to the technical field of traditional Chinese medicine extraction, and particularly relates to an extraction method of a high-activity ginseng extract, which is used for improving the conversion and extraction efficiency of rare ginsenoside Rg1, Rg3, Rg5, Rh2 and Compound K. The extraction method combines microbial fermentation, electrostatic field wall breaking and supercritical CO2 extraction, the high-voltage pulse electric field induces ginseng cells to generate an electroporation effect, permeability of cell membranes and cell walls is improved, supercritical CO2 extraction has high cell permeability, the extraction rate and purity of ginsenoside are improved, and in addition, a catalytic promoter added in the extraction process is beneficial to conversion catalysis of rare ginsenoside components.

The invention belongs to the technical field of traditional Chinese medicines, and provides a pharmaceutical composition containing an effective component of American ginseng, a pharmaceutical preparation and application of the pharmaceutical composition and the pharmaceutical preparation in treating chronic obstructive pulmonary diseases. The pharmaceutical composition is prepared from the following components in parts by weight: 1 to 2 parts of ginsenoside Rg1, 1 to 2 parts of ginsenoside Rc, 0.5 to 1 part of oleanolic acid, 0.1 to 0.5 part of notoginsenoside R1 and 0.05 to 0.1 part of notoginsenoside Fe. Specific American ginseng saponin components are compounded, and the dosage of each component is optimized, so that the composition has remarkable effects of protecting the lung function of a COPD mouse caused by cigarette smoke exposure, inhibiting expression of inflammatory factors and relieving in-vivo oxidative stress injury, the repairing effect is remarkable, and in order to improve the effect of American ginseng in treatment of COPD, the composition has a good application prospect. And an important basis is provided for fully exerting the effects of all active components in the American ginseng.

The invention relates to the technical field of health-care food, in particular to a pseudo-ginseng oral liquid and a preparation method and application thereof, and the pseudo-ginseng oral liquid comprises the following components in percentage by weight: 20-40% of pseudo-ginseng root extract, 3-8% of pseudo-ginseng stem and leaf extract, 0.5-2% of pseudo-ginseng flower extract and the balance of purified water. The total saponin is not less than 1200 mg / 100 mL in terms of ginsenoside Re, the ginsenoside Rb1 is not less than 30 wt%, the ginsenoside Rg1 is not less than 25 wt%, and the notoginsenoside R1 is not less than 5 wt%. The pH value of the product is 4.5-7.5, the product meets strict physicochemical and microbial standards, the product is packaged by a sodium-calcium glass bottle, and the shelf life is 24 months. The preparation method comprises the following steps: exclusively extracting, purifying, preparing, sterilizing and the like, and realizing quality controllability through an HPLC (High Performance Liquid Chromatography) characteristic chromatogram. The preparation is reasonable in dosage form, the problems of moisture absorption, low bioavailability and the like of a solid preparation are solved, and the active components are easy to absorb and convenient to take. Through research, the health-care tea has the health-care functions of improving hypoxia tolerance and relieving physical fatigue, and is suitable for people with related requirements.

The invention discloses an application of a compound composition containing astragaloside IV in preparation of a medicine for resisting plateau fatigue, and the compound composition containing astragaloside IV is prepared from the following raw materials in parts by weight: 500 to 2000 parts of astragaloside IV, 5000 to 20000 parts of ginsenoside Rg1, 2 to 5 parts of vitamin D3 and 30000 to 150000 parts of puerarin. Animal experiments prove that the compound composition can relieve plateau exercise fatigue, improve the hypoxia tolerance, exercise fatigue resistance and oxidative stress resistance of a body and improve the comprehensive exercise performance of the body. According to the invention, the defect of single-component efficacy is overcome, a compound preparation is designed in a targeted manner, an innovative and feasible compound combination is provided, and a new scheme is provided for promoting athletic performance under plateau hypoxia.

The application discloses a ginseng and astragalus root-danshen total phenolic acid heart function improving composition, and relates to the technical field of medicines.The active ingredients of the composition are composed of three chemical monomers of ginsenoside Rg1, astragaloside B and danshensu, and the weight ratio is 1:0.5 to 1:2 to 3.Through combination of the three specific monomers in the accurate proportion, multiple key nodes of myocardial cell energy metabolism can be synergistically regulated, and myocardial energy metabolism disorder under heart failure state can be systematically intervened.The composition has clear components, controllable quality, and can be prepared into various dosage forms such as tablets and capsules.Compared with medicinal material extracts with complex components, the composition provided by the application has the advantages of clear action mechanism, accurate proportion, stable quality and the like, and provides a new drug selection for the treatment of heart failure.

The invention belongs to the technical field of cobalt ginseng extraction processes, and particularly relates to a ginseng extract, a preparation method thereof and application of the ginseng extract in feed. The preparation method of the ginseng extract comprises the following steps: carrying out flocculation and impurity removal treatment on a ginseng enzymolysis extracting solution by adopting a graft copolymerization quaternized chitosan flocculant suspension, and purifying a flocculated supernatant, so as to obtain the ginseng extract, the dosage of the graft copolymerization quaternized chitosan flocculant suspension is 0.5%-1.5% of the volume of the ginseng enzymolysis extracting solution. According to the preparation method of the ginseng extract provided by the invention, the compound enzymolysis method, the selective flocculant impurity removal and the macroporous resin adsorption are cooperated, so that the prepared ginseng extract is high in purity, and various effective components such as ginsenoside Rg1, Rb1 and Re are reserved.

The present application provides a kind of pharmaceutical composition with lipid-lowering effect, including luteolin, isorhamnetin, 9-hydroxy-4,7-megastigme-3-ketone, lotus leaf base, 3-O-feruloyl quinic acid, kaempferol-3-O-acacia disaccharide-7-O-glucoside, kaempferol-3-O-beta-D-acacia glycoside and ginsenoside Rg1.The composition of example 1 has lipid-lowering efficacy verified by golden hamster hyperlipidemia model and AML12, HepG2 cell fatty degeneration model, the regulation effect of the composition of example 1 on the key target points of AMPK signal pathway and NF-κB signal pathway is verified by using molecular pharmacology experiment, and the mechanism of the composition of example 1 in treating hyperlipidemia by regulating energy metabolism and anti-inflammatory mechanism is described.

The present application relates to the technical field of compound analysis, and in particular to a quality analysis method of ginseng medicinal materials, comprising the following steps: S100, preparation of a control solution: taking ginsenoside Rg1 control product, ginsenoside Re control product, ginsenoside Rf control product, ginsenoside Rb1 control product, ginsenoside Rc control product, ginsenoside Rb2 control product, ginsenoside Rd control product, 3-O-feruloylquinic acid control product, 4-coumaric acid control product, 8-O-4 / 8-O-4 dehydrogenated tri-ferulic acid control product, and adding methanol to prepare a mixed solution, and shaking to obtain the control solution. The present application synchronously monitors two components of saponins and phenolic acids under one detection method, monitors ten component contents of seven saponin components and three polyphenol components, obtains characteristic spectra of saponin components and polyphenol components, and the monitoring quality is more comprehensive and efficient.

The invention discloses a construction method of a finger-print spectrum of a styptic capsule and application of the styptic capsule in quality detection, and belongs to the field of Chinese patent medicine detection. The method comprises the following steps: firstly, adding 80% methanol solution into contents of different batches of Xuezhenning capsules for extraction to prepare Xuezhenning capsule test solution; the method comprises the following steps: taking ginsenoside Rg1, notoginsenoside R2, ginsenoside Rd, caffeic acid, isorhamnetin, verbascoside, aesculetin, ferulic acid, rutin and quercetin as reference substances, and preparing a reference substance solution; respectively injecting the test solution and the reference solution into a high performance liquid chromatograph to obtain corresponding chromatograms; performing similarity analysis on the chromatogram of the test solution; and finally, according to the chromatogram of the test solution and the chromatogram of the reference substance solution, combining a total ion chromatogram obtained by the high-resolution mass spectrum and a mass spectrum result map of the chemical components to construct the fingerprint spectrum of the styptic Ning capsule. The method can be used for simultaneously detecting 10 components in the haemostatic Ning capsule, and can be used for accurately, clearly and objectively evaluating the quality of the haemostatic Ning capsule.

The application discloses an application of a kit for detecting a SNP molecular marker related to the content of ginsenoside Rg1 in panax notoginseng in breeding of the content of ginsenoside Rg1 in panax notoginseng, wherein the SNP molecular marker is SNP10-117646255, is located at the 117646255th base of a Chr11 chromosome, and the mutation type is T / A. The KASP primer combination developed in the application can accurately distinguish panax notoginseng with high and low contents of ginsenoside Rg1, and can be applied to molecular assisted marker breeding of panax notoginseng, shortens the breeding cycle of new varieties, and has low detection cost, is not limited by environment, has high accuracy of detection results, and is easy to repeat. The application has important theoretical and practical guiding significance for accelerating the genetic improvement process of panax notoginseng with high content of ginsenoside Rg1 and improving the breeding selection efficiency.

The invention discloses a composition for improving emotion and sleep and a preparation method, and the composition for improving emotion and sleep comprises the following components in parts by weight: 10-30 parts of a ginseng extract, 100-300 parts of gamma-aminobutyric acid, 50-150 parts of tea leaf theanine, and 50-200 parts of a spina date seed extract. The ginsenoside Rg1 + Rb1 in the ginseng extract is greater than or equal to 3%, the purity of gamma-aminobutyric acid is greater than or equal to 99%, the purity of theanine in tea leaves is greater than or equal to 98%, and the saponin content in the spina date seed extract is greater than or equal to 2%; the composition inhibits secretion of stress hormone through a multi-target synergistic effect, regulates nervous excitability and prolongs a deep sleep period, and is used for relieving mild and moderate anxiety, improving difficulty in falling asleep and improving sleep quality. According to the invention, the problems of single effect, dependence risk, slow effect and the like of the existing product can be solved, and the double effects of emotion regulation and sleep improvement are integrated.

The invention relates to the technical field of medicine application, in particular to application of ginsenoside Rg1 in preparation of a medicine for improving cisplatin-induced renal injury. The invention discloses application of ginsenoside Rg1 in preparation of a medicine for improving cisplatin-induced renal injury. It is proved for the first time that ginsenoside Rg1 has prevention and protection effects on cisplatin-induced acute kidney injury; it is proved that the ginsenoside Rg1 is related to cell autophagy in relieving the cisplatin-induced acute kidney injury; the JAK2-STAT3 pathway is proposed to be possibly an action pathway of the ginsenoside Rg1 for relieving the acute kidney injury induced by the cis-platinum; the LCP1 is proposed to be possibly an action target of the ginsenoside Rg1 for relieving the cisplatin-induced acute kidney injury.

The invention discloses a composition for reducing liver injury. The composition for reducing liver injury comprises fucoidin and ginsenoside Rg1 in a mass ratio of (1-3): (1-3). Comprising fucoidin and ginsenoside Rg1 can be applied to preparation of drugs for relieving liver injury, drugs for promoting tissue blood supply and drugs for relieving NETs accumulation in the liver. It is found for the first time that chemotherapeutic drugs cause intestinal barrier damage, then LPS enters blood, and NETs-mediated inflammatory response is induced to aggravate in the liver. Based on pathogenesis study of the liver injury, on one hand, fucoidin and ginsenoside Rg1 are combined to reduce generation of NETs, inhibit accumulation of NETs in the liver and inhibit TF and MMP9 at the same time, and finally the liver injury is relieved; on the other hand, the fucoidin is combined with ginsenoside Rg1, so that intestinal barriers can be protected, LPS entering blood is reduced, tissue blood supply is promoted, and chemotherapy-induced liver injury is relieved.

The application provides a multi-component quantitative analysis method of anti-aging tablets, acetonitrile-0.1% formic acid aqueous solution is used as a mobile phase, an HSS T3 chromatographic column is used for target compound separation, and 13 active components in the anti-aging tablets are simultaneously determined in an MRM mode by using an electrospray ionization triple quadrupole mass spectrometer, the linear range of the 13 active components is 0.4-100 ng / mL, the linear range of ginsenoside Rb1, ginsenoside Rb2, ginsenoside Rc, ginsenoside Rd, ginsenoside Re, ginsenoside Rf and ginsenoside Rg1 is 4-1000 ng / mL, the method has high sensitivity, strong specificity and good reproducibility, and realizes simultaneous quantitative analysis of the 13 active components in the anti-aging tablets.

The invention discloses a compound melanterite pill specific chromatogram and a construction method and a quality detection method thereof, and belongs to the field of Chinese patent medicine detection. Taking different batches of compound melanterite pills as test articles to prepare a compound melanterite pill test article solution; the method comprises the following steps: taking gallic acid, ginsenoside Rg1, procyanidine B2, cinnamic acid, coumarin, ginsenoside Rh1, cinnamyl alcohol, cinnamaldehyde, arachidonic acid, epicatechin, 2-methoxycinnamic acid, ginsenoside Rb1, ginsenoside Rd, betulinic acid and 5-hydroxymethylfurfural as reference substances to prepare a single reference substance solution; performing chromatographic analysis on the compound melanterite pill test solution and the single reference substance solution, and recording chromatograms; carrying out similarity analysis; and constructing the characteristic chromatogram of the compound melanterite pill according to the chromatogram of the test solution of the compound melanterite pill and the chromatogram of the single reference substance solution in combination with the total ion chromatogram obtained by the high-resolution mass spectrum and the mass spectrum result map of the chemical components. The method can accurately, clearly and objectively evaluate the quality of the compound melanterite pill.

The invention relates to a method for increasing the content of ginsenoside Rg1 in panax notoginseng cells, and belongs to the technical field of biology, the method comprises the following steps: (a) constructing a CRISPR / Cas9 expression vector; (b) introducing the expression vector into pseudo-ginseng cells by adopting an agrobacterium tumefaciens-mediated genetic transformation method, and carrying out infection and co-culture; (c) carrying out sterilization and selective culture on the co-cultured pseudo-ginseng cells, and screening out pseudo-ginseng positive cells which are successfully introduced into the expression vector and have specific resistance; (d) carrying out molecular identification on the screened pseudo-ginseng positive cells; and (e) measuring the content of ginsenoside Rg1. A CRISPR / Cas9 gene editing technology is utilized, a key enzyme CAS for competitively inhibiting synthesis of ginsenoside Rg1 in panax notoginseng cells is knocked out in a targeted mode, the key enzyme CAS is guided into the panax notoginseng cells through an agrobacterium-mediated genetic transformation method, and therefore a panax notoginseng cell line with the high ginsenoside Rg1 content is obtained through screening, and the ginsenoside Rg1 content of the panax notoginseng cells is remarkably increased.

The invention discloses a traditional Chinese medicine composition for enhancing functions of mature skeletal muscle cells and application of the traditional Chinese medicine composition. The composition is prepared from ginseng, astragalus membranaceus, pericarpium citri reticulatae, dogwood and rhizoma polygonati according to a specific ratio. The invention also provides an establishment method based on the quality standard of various active components (ginsenoside Rg1, hesperidin and the like) in the composition. The traditional Chinese medicine composition disclosed by the invention does not have a remarkable activity promoting effect on undifferentiated C2C12 myoblasts in a proliferation period, but can specifically enhance the cell activity of differentiated mature C2C12 myotubular cells. The action characteristics of the cell state dependence show that the composition does not simply stimulate cell proliferation, but is targeted to improve the functional state of mature muscle cells, so that a high-precision solution is provided for treating diseases (such as sarcopenia) characterized by mature muscle fiber function decline.

The invention discloses a method for detecting saponin components in ginseng and a preparation thereof. Relates to the field of medicinal material detection. The method for detecting the saponin components in the ginseng and the ginseng preparation comprises the following steps: S1, taking a ginseng sample or a ginseng-containing preparation, adding an extraction solvent, and extracting to obtain a test solution; s2, the test solution is injected into a liquid chromatograph, a chromatographic column is adopted for gradient elution, and octadecylsilane chemically bonded silica is adopted as a filling agent of the chromatographic column; s3, detecting pseudo-ginsenoside F11, ginsenoside Rf, ginsenoside Rg1, ginsenoside Rb1 and ginsenoside Re by adopting an electrospray ionization source negative ion mode and a multi-reaction monitoring mode of a mass spectrometry detector; a mobile phase used for gradient elution is selected from acetonitrile-water, an acetonitrile-ammonium acetate solution, acetonitrile-ammonium formate, methanol-formic acid or an acetonitrile-tetrahydrofuran-ammonium formate solution. By combining C18 chromatographic column gradient elution with a mass spectrum multi-reaction monitoring (MRM) mode and providing a mobile phase system, the problems of narrow applicability, isomeride interference, strong matrix effect and the like of a method for detecting saponin components of ginseng and preparations thereof in the prior art are effectively solved.

The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition for preventing or treating ischemic encephalopathy and application thereof, and the pharmaceutical composition comprises ginsenoside Rg1, ruscogenin and schizandrin. In an in-vitro oxygen-sugar deficiency / reperfusion induced bEnd.3 cell injury model, compared with a corresponding monomer component, the pharmaceutical composition disclosed by the invention can obviously recover the cell activity. In an in-vivo rat middle cerebral artery obstruction reperfusion model, the pharmaceutical composition disclosed by the invention can be used for remarkably reducing the cerebral infarction volume, improving the neural behavior function and recovering cerebral blood flow in an ischemic area. Meanwhile, toxicity is not shown in the continuous administration period. The results show that the pharmaceutical composition has an application prospect in treatment of cerebral arterial thrombosis, especially in improvement of ischemia reperfusion prognosis by restoring blood flow.

The present application belongs to the technical field of traditional Chinese medicine extraction, and particularly relates to an extraction method of high-activity ginseng extract, which is used for improving the conversion and extraction efficiency of rare ginsenosides Rg1, Rg3, Rg5, Rh2 and Compound K. The extraction method combines microbial fermentation, electrostatic field wall breaking and supercritical CO2 extraction. The microbial fermentation treatment is mainly used for promoting the synthesis of ginsenosides, the high-voltage pulse electric field induces the electroporation effect of ginseng cells to increase the permeability of cell membrane and cell wall, the supercritical CO2 extraction has high cell permeability to improve the extraction rate and purity of ginsenosides, and in addition, the catalytic aid added in the extraction process is helpful to the conversion and catalysis of rare ginsenoside components.

The invention discloses a ginsenoside composition and an application thereof, and particularly relates to an application of the ginsenoside composition in preparation of a medicine for treating asthma. The core of the composition is that the composition comprises the following components in specific parts by weight: 4-8 parts of ginsenoside Rg1 and 1-3 parts of ginsenoside Rb1, and 2-4 parts of total ginsenoside which takes effect together with one of the ginsenoside Rg1 and the ginsenoside Rb1 and is prepared through standardization, and the total content of the Rg1 and the Rb1 in the total ginsenoside is 50-70%. According to the present invention, the known pure saponin product and the standardized total saponin rich in the specific unknown saponin group are combined according to the specific ratio so as to produce the unexpected synergistic effect; pharmacodynamic experiments prove that the composition can significantly improve asthma symptoms and effectively inhibit airway inflammation, mucus hypersecretion and immune imbalance, and the curative effect of the composition is significantly superior to that of a single component or common total saponins. Meanwhile, the product quality is stable and controllable through a specific extraction and purification process.